ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 36

IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus

Joan E. Wither1, Nan-Hua Chang2, Timothy Li3, Julie Kim4, Carolina Landolt-Marticorena5, Paul R. Fortin6, Dafna D. Gladman7 and Murray B. Urowitz8, 11E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 6Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cell Function and Targeting in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization.  However the precise B cell populations that are affected and the mechanisms leading to this hyper-responsiveness have yet to be determined.  In this study we have used Phosflow to address these questions.

Methods: PBMC were isolated from 27 healthy controls and 39 SLE patients with ≥ 4 ACR criteria.  Phosflow was used to assess the levels of p-SYK, p-PLCγ2, or p-ERK following Ig receptor engagement with goat anti-human IgM F(ab’)2in distinct B cell subsets defined by anti-CD19,-CD27, -IgD, -IgM and -CD38.  B cell proliferation and apoptosis following anti-IgM stimulation were assessed by flow cytometry, using CFSE and annexin V staining, respectively.  For some experiments, healthy control B cells were incubated with IFN-α, or 50% plasma ± anti-IFN or irrelevant Ab.  Lupus associated SNPs were determined by TaqMan genotyping.

Results: There were increased basal levels of p-SYK and p-ERK in naïve B cells (CD19+CD27–IgD+) from lupus patients as compared to controls.  The levels of basal p-SYK correlated with CD86 expression suggesting that these cells had already been activated in-vivo.  Following crosslinking with anti-IgM, there was a significant increase in the proportion of p-SYK+ cells above basal levels in the naïve B cell population of lupus patients as compared to controls. Similar trends were seen for the proportion of p-PLCγ2+ and p-ERK+ cells.  The increases seen in p-SYK+ cells were most marked for the transitional B cell subset (CD19+CD27–IgD+CD38hiIgMhi), where the levels of p-SYK correlated with enhanced proliferation and survival.   There was no correlation between lupus associated SNPs in BLK, LYN, PTPN22, and CSK, and the proportion of p-SYK+ cells following IgM crosslinking.  The proportion of p-SYK+cells in the transitional B cell subset fluctuated between visits, suggesting a possible role for pro-inflammatory factors.  Consistent with this, incubation of lupus plasma with control B cells enhanced SYK phosphorylation following IgM crosslinking, which was blocked by pre-incubation of plasma with anti-IFN but not irrelevant Ab.  Incubation of healthy control cells with recombinant IFN-α enhanced SYK phosphorylation, proliferation, and survival following IgM crosslinking, particularly of the transitional B cell subset.

Conclusion: IFN-α alters transitional B cell function leading to enhanced survival and proliferation.  As purging of transitional B cells plays an important role in preventing autoreactive B cells from entering the mature B cell pool, it is likely that elevated levels of IFN-α exacerbate the breach of B cell tolerance in lupus.


Disclosure:

J. E. Wither,
None;

N. H. Chang,
None;

T. Li,
None;

J. Kim,
None;

C. Landolt-Marticorena,
None;

P. R. Fortin,
None;

D. D. Gladman,

Janssen, Abbvie, Amgen, Pfizer, UCB, Novartis, Lily, Celgene,

2,

Janssen, Abbvie, Amgen, Pfizer, UCB, Novartis, Lily, Celgene,

5;

M. B. Urowitz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ifn-%ce%b1-induces-altered-transitional-b-cell-signaling-and-function-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology